keyword
MENU ▼
Read by QxMD icon Read
search

DMARD

keyword
https://www.readbyqxmd.com/read/29033678/quantitative-metabolic-volumetric-product-on-18-fluorine-2fluoro-2-deoxy-d-glucose-positron-emission-tomography-computed-tomography-in-assessing-treatment-response-to-disease-modifying-antirheumatic-drugs-in-rheumatoid-arthritis-multiparametric-analysis-integrating
#1
Nandigam Santosh Kumar, Yogesh Shejul, Ramesh Asopa, Sandip Basu
The purpose of this study was to assess the role of fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography (FDG-PET/CT) in the evaluation of treatment response evaluation to disease-modifying antirheumatic drug (DMARD) therapy in patients of rheumatoid arthritis (RA). A total of ten patients with proven diagnosis of RA as per the 2010 American College of Rheumatology/European League against Rheumatism (EULAR) criteria were prospectively evaluated. All patients underwent clinical and biochemical evaluation and a baseline FDG-PET/CT with assessment of maximum standardized uptake value and metabolic volumetric product (MVP) values...
October 2017: World Journal of Nuclear Medicine
https://www.readbyqxmd.com/read/29032909/subclinical-synovitis-measured-by-ultrasound-in-rheumatoid-arthritis-patients-with-clinical-remission-induced-by-synthetic-and-biological-modifying-disease-drugs
#2
Marcos Cruces, Soham Al Snih, Natalí Serra-Bonett, Juan C Rivas
BACKGROUND: Rheumatoid arthritis (RA) patients with disease in clinical remission might show subclinical synovitis, which can be related to the progress of structural joint damage. OBJECTIVE: To determine and compare the degree of synovial inflammation by ultrasound (US) in patients with RA in clinical remission, treated with DMARD or combination therapy with DMARD and anti-TNF. METHODS: Hospital-based cross-sectional study of 58 patients with RA in sustained remission for at least 6 months by DAS28 <2...
October 9, 2017: Reumatología Clinica
https://www.readbyqxmd.com/read/29029308/difficult-to-treat-rheumatoid-arthritis-an-area-of-unmet-clinical-need
#3
Maria J H de Hair, Johannes W G Jacobs, Jan L M Schoneveld, Jacob M van Laar
Increased effectiveness of pharmacological treatments in early RA has led many to believe that difficult-to-treat, established RA is a condition of the past. However, there are still plenty of RA patients who continue to have signs and symptoms suggestive of inflammatory disease activity, despite consecutive treatment with multiple conventional synthetic and biological DMARDs. We argue that difficult-to-treat RA constitutes an area of unmet clinical need and propose a definition of this concept. An overview of what is known about the multiple contributory factors varying for each individual patient, and an approach towards improved patient-tailored management are presented...
October 4, 2017: Rheumatology
https://www.readbyqxmd.com/read/29029185/patient-reported-outcomes-in-newly-diagnosed-early-rheumatoid-arthritis-patients-treated-to-target-with-a-tocilizumab-or-methotrexate-based-strategy
#4
Xavier M Teitsma, Johannes W G Jacobs, Paco M J Welsing, Attila Pethö-Schramm, Michelle E A Borm, Lidy Hendriks, Natasja H A M Denissen, Jacob M van Laar, Floris P J G Lafeber, Johannes W J Bijlsma
Objective: To evaluate the effect of initiation of tocilizumab, with or without MTX, compared with MTX alone on patient-reported outcomes (PROs), in DMARD-naïve patients with early RA. Methods: In U-Act-Early, patients initiated treat-to-target step-up MTX, tocilizumab or tocilizumab plus MTX therapy. PROs assessed included the Functional Assessment of Chronic Illness Therapy-Fatigue, 36-item Short Form (SF-36), five dimensional EuroQol (EQ-5D) and the Revised Illness Perception Questionnaire...
September 23, 2017: Rheumatology
https://www.readbyqxmd.com/read/28990250/galectin-3-is-persistently-increased-in-early-rheumatoid-arthritis-ra-and-associates-with-anti-ccp-seropositivity-and-mri-bony-lesions-while-early-fibrosis-markers-correlate-with-disease-activity
#5
Saida Farah Issa, Anne Friesgaard Christensen, Hanne M Lindegaard, Merete L Hetland, Kim Hørslev-Petersen, Kristian Stengaard-Pedersen, Bo Jannik Ejbjerg, Tine Lottenburger, Torkell Ellingsen, Jens Kristian Pedersen, Kirsten Junker, Anders Svendsen, Ulrik Tarp, Mikkel Østergaard, Peter Junker
Galectin-3 has been suggested as a pro-inflammatory mediator in animal arthritis and rheumatoid arthritis (RA). We aimed to study the serum level of galectin-3 in patients with newly diagnosed RA and associations with disease profile, Magnetic Resonance Imaging (MRI) findings and seromarkers of synovial matrix inflammation. One hundred and sixty DMARD naïve patients newly diagnosed with RA were included (CIMESTRA study). Clinical, serological and imaging data were recorded before treatment and at 6 weeks, 3 and 12 months...
October 9, 2017: Scandinavian Journal of Immunology
https://www.readbyqxmd.com/read/28976302/certolizumab-pegol-and-secukinumab-for-treating-active-psoriatic-arthritis-following-inadequate-response-to-disease-modifying-antirheumatic-drugs-a-systematic-review-and-economic-evaluation
#6
Mark Corbett, Fadi Chehadah, Mousumi Biswas, Thirimon Moe-Byrne, Stephen Palmer, Marta Soares, Matthew Walton, Melissa Harden, Pauline Ho, Nerys Woolacott, Laura Bojke
BACKGROUND: Several biologic therapies are approved by the National Institute for Health and Care Excellence (NICE) for psoriatic arthritis (PsA) patients who have had an inadequate response to two or more synthetic disease-modifying antirheumatic drugs (DMARDs). NICE does not specifically recommend switching from one biologic to another, and only ustekinumab (UST; STELARA(®), Janssen Pharmaceuticals, Inc., Horsham, PA, USA) is recommended after anti-tumour necrosis factor failure. Secukinumab (SEC; COSENTYX(®), Novartis International AG, Basel, Switzerland) and certolizumab pegol (CZP; CIMZIA(®), UCB Pharma, Brussels, Belgium) have not previously been appraised by NICE...
October 2017: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/28974987/sustained-remission-in-rheumatoid-arthritis-latest-evidence-and-clinical-considerations
#7
REVIEW
Sofia Ajeganova, Tom Huizinga
Sustained remission is an ultimate treatment goal in the management of patients with rheumatoid arthritis (RA). Historically the frequency of sustained remission was low but the frequency of achieved sustained remission is increasing over time. The last years' clinical studies of tight control targeted treatment and intervention trials of early use of intensive strategy suggest that these treatment strategies are associated with higher rates of sustained remission. Achievement of sustained remission, in particular but not limited to early sustained remission, can provide tapering and stopping disease-modifying antirheumatic drugs (DMARDs)...
October 2017: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/28968858/optimizing-treatment-with-tumour-necrosis-factor-inhibitors-in-rheumatoid-arthritis-a-proof-of-principle-and-exploratory-trial-is-dose-tapering-practical-in-good-responders
#8
Fowzia Ibrahim, Beatriz Lorente-Cánovas, Caroline J Doré, Ailsa Bosworth, Margaret H Ma, James B Galloway, Andrew P Cope, Ira Pande, David Walker, David L Scott
Objectives: RA patients receiving TNF inhibitors (TNFi) usually maintain their initial doses. The aim of the Optimizing Treatment with Tumour Necrosis Factor Inhibitors in Rheumatoid Arthritis trial was to evaluate whether tapering TNFi doses causes loss of clinical response. Methods: We enrolled RA patients receiving etanercept or adalimumab and a DMARD with DAS28 under 3.2 for over 3 months. Initially (months 0-6) patients were randomized to control (constant TNFi) or two experimental groups (tapering TNFi by 33 or 66%)...
August 17, 2017: Rheumatology
https://www.readbyqxmd.com/read/28966211/initial-serological-response-after-prime-boost-pneumococcal-vaccination-in-rheumatoid-arthritis-patients-results-of-a-randomized-controlled-trial
#9
Mai T T Nguyen, Hanne Lindegaard, Oliver Hendricks, Charlotte Sværke Jørgensen, Bjørn Kantsø, Nina Friis-Møller
OBJECTIVE: To evaluate the initial serological responses to pneumococcal vaccination with the 13-valent protein-conjugated pneumococcal vaccine (PCV13) followed by the 23-valent polysaccharide pneumococcal vaccine (PPV23) among patients with rheumatoid arthritis (RA) treated with biological disease-modifying antirheumatic drugs (bDMARD) according to dosing and intervals between immunizations. METHODS: Investigator-initiated clinical trial. Patients with RA receiving bDMARD were randomized (1:1:1) to immunization with single dose PCV13 followed by PPV23 after 16 or 24 weeks, or double dose PCV13 followed by PPV23 after 16 weeks...
October 1, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/28963724/the-anti-cd6-antibody-itolizumab-provides-clinical-benefit-without-lymphopenia-in-rheumatoid-arthritis-patients-results-from-a-6-month-open-label-phase-i-clinical-trial
#10
Pedro C Rodríguez, Dinorah M Prada, Ernesto Moreno, Lazaro E Aira, Claudino Molinero, Ana M Lopez, Jorge A Gómez, Isabel M Hernandez, Jose P Martinez, Yusimi Reyes, Joel M Milera, Maria V Hernandez, Roberto Torres, Yisel Avila, Yinet Barrese, Carmen Viada, Enrique Montero, Patricia Hernández
Itolizumab is a humanized anti-CD6 monoclonal antibody (mAb) that has previously shown encouraging results, in terms of safety and positive clinical effects, in a 6-week monotherapy clinical trial conducted in RA patients. The current phase I study evaluated the safety and clinical response for a longer treatment of 12 itolizumab intravenous doses in subjects with active RA despite previous DMARD therapy. Twenty one subjects were enrolled in four dose groups (0.1, 0.2, 0.4 and 0.8 mg/kg). Efficacy endpoints including American College of Rheumatology (ACR)20, ACR50 and ACR70 response rates and Disease Activity Score in 28 joints (DAS28) were monitored at baseline and at specific time points over a 10-week follow-up period...
September 30, 2017: Clinical and Experimental Immunology
https://www.readbyqxmd.com/read/28952204/disease-activity-trajectories-in-early-rheumatoid-arthritis-following-intensive-dmard-therapy-over-3-years-association-with-persistence-to-therapy
#11
Nasir Wabe, Jessica Wojciechowski, Mihir D Wechalekar, Leslie G Cleland, Leah McWilliams, Anita Lee, Susanna Proudman, Michael D Wiese
OBJECTIVE: To identify the disease activity trajectories during intensive triple disease modifying anti-rheumatic drug (DMARD) therapy over 3 years in rheumatoid arthritis (RA) patients and to evaluate the association with treatment persistence. METHODS: Disease Activity Score in 28 joints, baseline risk factors and medication usage were obtained from a longitudinal observational cohort of early RA patients, most of whom were treated with combination DMARD therapy consisting of methotrexate, sulfasalazine and hydroxychloroquine...
September 26, 2017: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/28947313/effectiveness-of-biologic-and-non-biologic-antirheumatic-drugs-on-anaemia-markers-in-153-788-patients-with-rheumatoid-arthritis-new-evidence-from-real-world-data
#12
Sanjoy Ketan Paul, Olga Montvida, Jennie H Best, Sara Gale, Attila Pethoe-Schramm, Khaled Sarsour
BACKGROUND: To evaluate the impact of treatment with disease-modifying antirheumatic drugs (DMARDs), including IL-6 receptor inhibitor tocilizumab (TCZ), on anaemia markers in patients with rheumatoid arthritis. METHODS: Using the Centricity Electronic Medical Records from USA, patients with rheumatoid arthritis diagnosed between January 2000 and April 2016, who initiated TCZ (n = 3732); tofacitinib (TOFA, n = 3126); other biologic DMARD (obDMARD, n = 55,964); or other non-biologic DMARD (onbDMARD, n = 91,236) were identified...
August 3, 2017: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/28944162/an-update-on-treatment-of-pediatric-chronic-non-infectious-uveitis
#13
Arjun B Sood, Sheila T Angeles-Han
There are no standardized treatment protocols for pediatric non-infectious uveitis. Topical corticosteroids are the typical first-line agent, although systemic corticosteroids are used in intermediate, posterior and panuveitic uveitis. Corticosteroids are not considered to be long-term therapy due to potential ocular and systemic side effects. In children with severe and/or refractory uveitis, timely management with higher dose disease-modifying antirheumatic drugs (DMARDs) and biologic agents is important...
March 2017: Current Treatment Options in Rheumatology
https://www.readbyqxmd.com/read/28941221/how-well-do-rheumatology-fellows-manage-acute-infusion-reactions-a-pilot-curricular-intervention
#14
Jason J Weiner, Amanda M Eudy, Lisa G Criscione-Schreiber
BACKGROUND: Infusible DMARDs are commonly prescribed in rheumatology and other fields. There are no published formal educational curricula rheumatology fellowship programs can use to teach infusion reaction management skills to fellows. We aimed to better understand this educational gap, and implement and assess the effectiveness of an experiential curriculum on acute infusion reaction management. METHODS: We included current rheumatology fellows and recent graduates from five fellowship programs...
September 21, 2017: Arthritis Care & Research
https://www.readbyqxmd.com/read/28941219/lymphoma-in-the-tofacitinib-rheumatoid-arthritis-clinical-development-program
#15
Xavier Mariette, Connie Chen, Pinaki Biswas, Kenneth Kwok, Mary G Boy
BACKGROUND: Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). We characterized lymphoma events in the tofacitinib RA clinical development program. METHODS: Lymphoma events (to March 2015) were identified from 19 tofacitinib studies (two Phase 1, nine Phase 2, six Phase 3, and two long-term extension) of patients with moderate to severe RA. Patients in these studies received tofacitinib dosed at 1-30 mg twice daily or 20 mg once daily, as monotherapy or with conventional synthetic DMARDs...
September 21, 2017: Arthritis Care & Research
https://www.readbyqxmd.com/read/28941147/timing-and-impact-of-decisions-to-adjust-disease-modifying-antirheumatic-drug-therapy-for-rheumatoid-arthritis-patients-with-active-disease
#16
Yomei Shaw, Chung-Chou H Chang, Marc C Levesque, Julie M Donohue, Kaleb Michaud, Mark S Roberts
OBJECTIVE: Guidelines recommend that rheumatoid arthritis (RA) patients with moderate to high disease activity (MHDAS) adjust disease-modifying antirheumatic drug (DMARD) therapy at least every 3 months until reaching low disease activity or remission (LDAS). We examined how quickly RA patients with MHDAS adjust DMARD therapy in clinical practice, and whether those who adjust DMARDs within 90 days in response to MHDAS reach LDAS sooner. METHODS: We identified RA patients with MHDAS in the University of Pittsburgh Rheumatoid Arthritis Comparative Effectiveness Research (RACER) registry, and conducted a competing risks regression on time to DMARD therapy adjustment and a Cox regression on time to LDAS...
September 21, 2017: Arthritis Care & Research
https://www.readbyqxmd.com/read/28941039/a-randomized-phase-iib-study-of-mavrilimumab-and-golimumab-in-rheumatoid-arthritis
#17
Michael E Weinblatt, Iain B McInnes, Joel M Kremer, Pedro Miranda, Jiri Vencovsky, Xiang Guo, Wendy I White, Patricia C Ryan, Alex Godwood, Marius Albulescu, David Close, Gerd R Burmester
OBJECTIVE: This 24-week, Phase IIb, double-blind study (NCT01715896) evaluated mavrilimumab (anti-granulocyte-macrophage colony-stimulating factor [GM-CSFR]-α monoclonal antibody) and golimumab (anti-tumor necrosis factor [TNF] monoclonal antibody) in patients with rheumatoid arthritis (RA), with inadequate responses to disease-modifying antirheumatic drugs (DMARD-IR) and/or anti-TNF agents (anti-TNF-IR). METHODS: Patients with active RA and DMARD-IR (≥1 failed regimen), or DMARD-IR (≥1 failed regimen) and anti-TNF-IR (1-2 failed regimens), were randomized 1:1 to subcutaneous mavrilimumab 100 mg every other week (eow) or golimumab 50 mg every 4 weeks (Q4W) alternating with placebo Q4W, plus concomitant methotrexate...
September 21, 2017: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/28937499/prognostic-factors-for-permanent-work-disability-in-patients-with-rheumatoid-arthritis-who-received-combination-therapy-of-conventional-synthetic-disease-modifying-antirheumatic-drugs-a-retrospective-cohort-study
#18
M Luisa Vazquez-Villegas, Jorge I Gamez-Nava, Alfredo Celis, Dalia Sanchez-Mosco, Liliana F de la Cerda-Trujillo, Jessica D Murillo-Vazquez, A Miriam Saldaña-Cruz, Miriam F Alcaraz-Lopez, Valeria Diaz-Rizo, Jose Alvarez-Nemegyei, Mario H Cardiel, Laura Gonzalez-Lopez
BACKGROUND: There is limited information about the factors related with the development of long-term permanent work disability (PWD) in rheumatoid arthritis (RA) treated with a combination of conventional synthetic disease-modifying antirheumatic drugs (cs-DMARDs). OBJECTIVE: The aim of this study was to evaluate incidence and factors associated with the development of PWD in RA treated with combination therapy using conventional synthetic cs-DMARDs. METHODS: We assessed in multivariate models the effect of clinical and demographic factors in the development of PWD in a long-term retrospective cohort of 180 workers with RA who were treated with a combination of cs-DMARDs...
September 21, 2017: Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases
https://www.readbyqxmd.com/read/28937473/prognostic-factors-for-permanent-work-disability-in-patients-with-rheumatoid-arthritis-who-received-combination-therapy-of-conventional-synthetic-disease-modifying-antirheumatic-drugs-a-retrospective-cohort-study
#19
M Luisa Vazquez-Villegas, Jorge I Gamez-Nava, Alfredo Celis, Dalia Sanchez-Mosco, Liliana F de la Cerda-Trujillo, Jessica D Murillo-Vazquez, A Miriam Saldaña-Cruz, Miriam F Alcaraz-Lopez, Valeria Diaz-Rizo, Jose Alvarez-Nemegyei, Mario H Cardiel, Laura Gonzalez-Lopez
BACKGROUND: There is limited information about the factors related with the development of long-term permanent work disability (PWD) in rheumatoid arthritis (RA) treated with a combination of conventional synthetic disease-modifying antirheumatic drugs (cs-DMARDs). OBJECTIVE: The aim of this study was to evaluate incidence and factors associated with the development of PWD in RA treated with combination therapy using conventional synthetic cs-DMARDs. METHODS: We assessed in multivariate models the effect of clinical and demographic factors in the development of PWD in a long-term retrospective cohort of 180 workers with RA who were treated with a combination of cs-DMARDs...
October 2017: Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases
https://www.readbyqxmd.com/read/28932292/methotrexate-blood-pressure-and-markers-of-arterial-function-in-patients-with-rheumatoid-arthritis-a-repeated-cross-sectional-study
#20
Arduino A Mangoni, Leena R Baghdadi, E Michael Shanahan, Michael D Wiese, Sara Tommasi, David Elliot, Richard J Woodman
BACKGROUND: Methotrexate (MTX) treatment in rheumatoid arthritis (RA) has been associated with lower cardiovascular risk compared to other disease-modifying antirheumatic drugs (DMARDs). We sought to identify whether the MTX-associated cardioprotection involves changes in blood pressure (BP) and/or arterial function. METHODS: Clinic and 24-hour peripheral and central systolic and diastolic BP (SBP and DBP), augmentation index (AIx), pulse wave velocity (PWV) and plasma asymmetric dimethylarginine (ADMA) were assessed in RA patients on stable treatment with either MTX ± other DMARDs (MTX group, n = 56, age 61 ± 13 years, 70% females) or other DMARDs (non-MTX group, n = 30, age 63 ± 12 years, 76% females)...
September 2017: Therapeutic Advances in Musculoskeletal Disease
keyword
keyword
61414
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"